MORRISVILLE, N.C., Nov. 24, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO, today announced the completion of the previously announced offering of $600.0 million aggregate principal amount of 3.625% senior notes due 2029. The Notes are guaranteed, jointly and severally, on a senior unsecured basis, by certain of the Company’s subsidiaries.

The net proceeds of the offering will be used for general corporate purposes, including the funding of acquisitions, and for repayment of indebtedness.

The Notes were offered only to persons reasonably believed to be qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States, only to non-U.S. investors pursuant to Regulation S. The Notes will not be and have not been registered under the Securities Act and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements.

The Company also announced that it entered into an amendment to the credit agreement governing its existing senior secured credit facilities pursuant to which, among other things, the Issuer has extended the maturity date thereof to August 2024.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers of the Notes were made only by means of a private offering memorandum.

About Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.